$Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients$
Código QR

Código QR

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Mostrar otras versiones (1)

CorrigendumNielsen SA, McDonald MB, Majmudar PA. Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients. Clinical Ophthalmology. 2013;7:149–156. The paper titled "Safety of besifloxacin ophthalmic suspension 0.6% in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nielsen SA, McDonald MB, Majmudar PA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/62887bf5ac5044139f2938998b9defcb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen SA, et al.
Publicado: (2013)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein BE, et al.
Publicado: (2012)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris TW, et al.
Publicado: (2011)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas W, et al.
Publicado: (2011)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau JM, et al.
Publicado: (2021)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
por: Malhotra R, et al.
Publicado: (2012)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci FA Jr, et al.
Publicado: (2015)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi MA
Publicado: (2018)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
por: Haas W, et al.
Publicado: (2013)

Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
por: Wang XJ, et al.
Publicado: (2011)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe ZT, et al.
Publicado: (2013)

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
por: Bruce I Gaynes, et al.
Publicado: (2008)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: William Stringer, et al.
Publicado: (2010)

Predictability and stability of refraction with increasing optical zone diameter in hyperopic LASIK
por: Mostafa A El-Helw, et al.
Publicado: (2010)

Refractive outcomes of an advanced aspherically optimized profile for myopia corrections by LASIK: a retrospective comparison with the standard aspherically optimized profile
por: Meyer B, et al.
Publicado: (2015)

Topography-modified refraction: adjustment of treated cylinder amount and axis to the topography versus standard clinical refraction in myopic topography-guided LASIK
por: Alpins N
Publicado: (2017)

Evaluation of dacryocystorhinostomy using optical coherence tomography and rebamipide ophthalmic suspension
por: Fujimoto M, et al.
Publicado: (2014)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

Topography-modified refraction (TMR): adjustment of treated cylinder amount and axis to the topography versus standard clinical refraction in myopic topography-guided LASIK
por: Kanellopoulos AJ
Publicado: (2016)

Efficacy of nepafenac ophthalmic suspension 0.1% in improving clinical outcomes following cataract surgery in patients with diabetes: an analysis of two randomized studies
por: Singh RP, et al.
Publicado: (2017)

Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal
por: Kashima T, et al.
Publicado: (2014)

The Prospective Health Assessment of Cataract Patients’ Ocular Surface (PHACO) study: the effect of dry eye
por: Trattler WB, et al.
Publicado: (2017)

Comparative study of FS-LASIK and FS-LASIK combined with accelerated corneal cross-linking for correction of high myopia in the early stage of refractive power and corneal high-order aberration
por: Wen-Jia Cao, et al.
Publicado: (2021)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
por: Timothy L Comstock, et al.
Publicado: (2010)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial
por: Nichols KK, et al.
Publicado: (2018)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

Comparison of visual acuity, refractive outcomes, and satisfaction between LASIK performed with a microkeratome and a femto laser
por: Hashmani S, et al.
Publicado: (2017)

ELECTRICAL BEHAVIOR OF A Cu2Fe0.4Co0.6SnS4 CERAMIC
por: LÓPEZ-VERGARA,FERNANDA, et al.
Publicado: (2013)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
por: Nichols KK, et al.
Publicado: (2018)

Vector Analysis Reveals That Topography-Guided LASIK Targeting the Manifest Refraction (MR) is Superior to Topography-Modified Refraction (TMR) and Layer Yolked Reduction of Astigmatism (LYRA) [Letter]
por: Wallerstein A, et al.
Publicado: (2021)

A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis
por: Pepose JS, et al.
Publicado: (2019)

Control-matched comparison of refractive and visual outcomes between small incision lenticule extraction and femtosecond laser-assisted LASIK
por: Kataoka T, et al.
Publicado: (2018)

Long-term bladeless LASIK outcomes with the FS200 Femtosecond and EX500 Excimer Laser workstation: the Refractive Suite
por: Kanellopoulos AJ, et al.
Publicado: (2013)

Vector Analysis Reveals That Topography-Guided LASIK Targeting the Manifest Refraction (MR) is Superior to Topography-Modified Refraction (TMR) and Layer Yolked Reduction of Astigmatism (LYRA) [Response to Letter]
por: Aboalazayem F, et al.
Publicado: (2021)

Evolution of the intrinsic electronic phase separation in La0.6Er0.1Sr0.3MnO3 perovskite
por: Lili Chen, et al.
Publicado: (2016)

Early access to physiotherapy for infants with cerebral palsy: A retrospective chart review.
por: Linnéa Hekne, et al.
Publicado: (2021)

Treatment patterns in diabetic macular edema in Taiwan: a retrospective chart review
por: Sheu SJ, et al.
Publicado: (2018)

Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review
por: Correia-Melo FS, et al.
Publicado: (2017)

Biomechanical Changes to the Cornea from LASIK Flap Creation Resulting in Inaccurate Ablations and Suboptimal Refractive Outcomes with Topographic-Guided Ablation
por: Motwani M
Publicado: (2020)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
por: Gail Torkildsen, et al.
Publicado: (2010)